Вы находитесь на странице: 1из 10

Early-Warning System on New Psychoactive Substances Operating Guidelines

Annex III EMCDDA-Europol Reporting Form

REPORTING FORM ON NEW


PSYCHOACTIVE DRUG

In accordance with Council Decision 2005/387/JHA of


10 May 2005 on information exchange, risk
assessment and control of new psychoactive
substances.

This section should be filled in by Europol or EMCDDA

Transmitted by Europol Transmitted by EMCDDA


Ref. nº: OEDT/EPI (08) D/30053 Date of transmission: 20/10/08

The following sections should be filled by the Europol National Units (ENU) or REITOX
National Focal Points (NFP) based on the information available and their respective
competences
1. Member State: UK Reporting authority:

Ref. n°: Date 15 October 2008 ENU REITOX


2. Chemical name: 4-Methylmethcathinone

Other name(s): The β-keto analogue of 4-methylmethamphetamine; 2-methylamino-


1-(4-methylphenyl)propan-1-one; mephedrone

Street name(s): Sub-coca I


3. Source of information (fill one or more as appropriate)

Seizure(s) Specify amount (weight, number of tablets, etc.):


Seizing authority:
Date: Place:
Biological sample(s)1 Specify type:
Identifying authority:
Date: Place:

Collected sample(s)2 Specify amount (weight, number of tablets, etc):

Collecting authority: TICTAC Communications, Toxicology Unit, St. George’s


Hospital Medical School, London, SW17 0RE.

Date: September 2008 Place: Obtained as a test purchase from


http://www.biorepublik.com/

Other substances present (if more than one case, specify for which one):

Psychoactive ingredients: All four products also contained ethcathinone (Sub-coca II;
ethylpropion).

Other ingredients: Products 1, 2 and 4 also contained caffeine

1
Biological (human) samples e.g. body fluids (urine, blood), tissues, hair, etc.
2
Actively collected by drug monitoring systems for monitoring or research purposes
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

4. Physical description (in case of seizure/collection)


Product 1:

Form: powder tablet capsule liquid other (specify):

Colour: Red

For dosage unit: weight: diameter: shape: logo/markings:


294mg 17.1mm x 6.1mm

4. Physical description (in case of seizure/collection)


Product 2:

Form: powder tablet capsule liquid other (specify):

Colour: Blue/white

For dosage unit: weight: diameter: shape: logo/markings:


316mg 17.1mm x 6.2mm

4. Physical description (in case of seizure/collection)


Product 3:

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


204mg 17.7mm x 6.1mm

4. Physical description (in case of seizure/collection)


Product 4:

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


230mg 17.2mm x 6.3mm wide

2
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

5. Circumstances: production trafficking distribution use

6. Price: retail (per dosage unit): wholesale:


€7 per capsule
7. Chemical precursors:
Not Known
8. Patterns of use:
Not Known
9. Other possible uses3:
Not Known
10. Effects in man
Not Known
Objectively observed:

Subjective (described by users):

11. Context of use


Not Known
User group(s):

Setting(s):

Availability at consumer level:


12. Indication on possible risks
Not Known
Health (individual):

Public health:

Social:
13. In case of production: large-scale small scale unknown

Has any form of organised crime been detected: yes no

14. In case of trafficking: large scale small scale unknown

national international

Has any form of organised crime been detected: yes no


15. In case of distribution: large-scale small scale unknown

Has any form of organised crime been detected: yes no

3
For example, for medical, industrial, ritual, cosmetic, etc., purposes

3
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III EMCDDA-Europol Reporting Form

REPORTING FORM ON NEW


PSYCHOACTIVE DRUG

In accordance with Council Decision 2005/387/JHA of


10 May 2005 on information exchange, risk
assessment and control of new psychoactive
substances.

This section should be filled in by Europol or EMCDDA

Transmitted by Europol Transmitted by EMCDDA


Ref. nº: OEDT/EPI (08) D/30055 Date of transmission: 20/10/08

The following sections should be filled by the Europol National Units (ENU) or REITOX
National Focal Points (NFP) based on the information available and their respective
competences
1. Member State: UK Reporting authority:

Ref. n°: Date:15 October 2008 ENU REITOX


2. Chemical name: 3-Fluoromethcathinone

Other name(s): The β-keto analogue of 3-fluoromethamphetamine; 2-methylamino-


1-(3-fluorophenyl)propan-1-one

Street name(s): Various


3. Source of information (fill one or more as appropriate)

Seizure(s) Specify amount (weight, number of tablets, etc.):


Seizing authority:
Date: Place:
Biological sample(s)1 Specify type:
Identifying authority:
Date: Place:

Collected sample(s)2 Specify amount (weight, number of tablets, etc):

Collecting authority: TICTAC Communications, Toxicology Unit, St. George’s


Hospital Medical School, London, SW17 0RE. Structure confirmed by synthesis of all three
isomers (2, 3 and 4- fluoromethcathinone) and by 1H, 13C and 19F NMR.

Date: August – September 2008 Place: Obtained as test purchases


from Internet suppliers. Products 1 - 4 from http://www.biorepublik.com/, product 5 from
http://www.everyonedoesit.com/, products 6 - 8 from http://www.futurelegals.co.uk/

Other substances present (if more than one case, specify for which one):

Psychoactive ingredients: None

Other ingredients: Products 2, 3, 4 and 5 contain caffeine

1
Biological (human) samples e.g. body fluids (urine, blood), tissues, hair, etc.
2
Actively collected by drug monitoring systems for monitoring or research purposes
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

4. Physical description (in case of seizure/collection)


Product 1: Yellow Capsules Biorepublik

Form: powder tablet capsule liquid other (specify):

Colour: Yellow

For dosage unit: weight: diameter: shape: logo/markings:


433mg 19.1mm x 6.6mm

4. Physical description (in case of seizure/collection)


Product 2: White Capsules Biorepublik

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


391mg 18.8mm x 6.6mm

4. Physical description (in case of seizure/collection)


Product 3: Yellow/White Capsules Biorepublik

Form: powder tablet capsule liquid other (specify):

Colour: Yellow/white

For dosage unit: weight: diameter: shape: logo/markings:


303mg 18.9mm x 6.6mm

4. Physical description (in case of seizure/collection)


Product 4: Orange Capsules Biorepublik

Form: powder tablet capsule liquid other (specify):

Colour: Orange

2
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

For dosage unit: weight: diameter: shape: logo/markings:


405mg 19.1mm x 6.4mm

4. Physical description (in case of seizure/collection)


Product 5: Charge +

Form: powder tablet capsule liquid other (specify):

Colour: Undecided

For dosage unit: weight: diameter: shape: logo/markings:


A small plastic pot containing a ziplock bag that contains about 200mg powder. It is
labelled as "novelty bath salts not for human consumption".

4. Physical description (in case of seizure/collection)


Product 6: S.C.D.

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


470mg 18.7mm x 6.7mm

4. Physical description (in case of seizure/collection)


Product 7: High Spirit

Form: powder tablet capsule liquid other (specify):

Colour: Yellow

For dosage unit: weight: diameter: shape: logo/markings:


430mg 18.8mm x 6.7mm

4. Physical description (in case of seizure/collection)


Product 8: Lift Neorganics

Form: powder tablet capsule liquid other (specify):

3
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

Colour: Orange/white

For dosage unit: weight: diameter: shape: logo/markings:


370mg 18.8mm x 6.8mm

5. Circumstances: production trafficking distribution use

6. Price: retail (per dosage unit): wholesale:


€7-12 per item
7. Chemical precursors:
Not Known
8. Patterns of use:
Not Known
9. Other possible uses3:
Not Known
10. Effects in man
Not Known
Objectively observed:

Subjective (described by users):

11. Context of use


Not Known
User group(s):

Setting(s):

Availability at consumer level:


12. Indication on possible risks
Not Known
Health (individual):

Public health:
Social:
13. In case of production: large-scale small scale unknown

Has any form of organised crime been detected: yes no

14. In case of trafficking: large scale small scale unknown

national international

Has any form of organised crime been detected: yes no


15. In case of distribution: large-scale small scale unknown

Has any form of organised crime been detected: yes no

3
For example, for medical, industrial, ritual, cosmetic, etc., purposes

4
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III EMCDDA-Europol Reporting Form

REPORTING FORM ON NEW


PSYCHOACTIVE DRUG

In accordance with Council Decision 2005/387/JHA of


10 May 2005 on information exchange, risk
assessment and control of new psychoactive
substances.

This section should be filled in by Europol or EMCDDA

Transmitted by Europol Transmitted by EMCDDA


Ref. nº: OEDT/EPI (08) D/30054 Date of transmission: 20/10/08

The following sections should be filled by the Europol National Units (ENU) or REITOX
National Focal Points (NFP) based on the information available and their respective
competences
1. Member State: UK Reporting authority:

Ref. n°: Date 15 October 2008 ENU REITOX


2. Chemical name: Ethcathinone

Other name(s): The β-keto analogue of N-ethylamphetamine; 2-ethylamino-1-


phenylpropan-1-one; ethylpropion; N-ethylcathinone

Street name(s): Sub-coca II


3. Source of information (fill one or more as appropriate)

Seizure(s) Specify amount (weight, number of tablets, etc.):


Seizing authority:
Date: Place:
Biological sample(s)1 Specify type:
Identifying authority:
Date: Place:

Collected sample(s)2 Specify amount (weight, number of tablets, etc):

Collecting authority: TICTAC Communications, Toxicology Unit, St. George’s


Hospital Medical School, London, SW17 0RE.

Date: September 2008 Place: Obtained as a test purchase from


http://www.biorepublik.com/

Other substances present (if more than one case, specify for which one):

Psychoactive ingredients: All four products also contained 4-methylmethcathinone (Sub-


coca I; mephedrone).

Other ingredients: Products 1, 2 and 4 also contained caffeine

1
Biological (human) samples e.g. body fluids (urine, blood), tissues, hair, etc.
2
Actively collected by drug monitoring systems for monitoring or research purposes
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

4. Physical description (in case of seizure/collection)


Product 1:

Form: powder tablet capsule liquid other (specify):

Colour: Red

For dosage unit: weight: diameter: shape: logo/markings:


294mg 17.1mm x 6.1mm

4. Physical description (in case of seizure/collection)


Product 2:

Form: powder tablet capsule liquid other (specify):

Colour: Blue/white

For dosage unit: weight: diameter: shape: logo/markings:


316mg 17.1mm x 6.2mm

4. Physical description (in case of seizure/collection)


Product 3:

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


204mg 17.7mm x 6.1mm

4. Physical description (in case of seizure/collection)


Product 4:

Form: powder tablet capsule liquid other (specify):

Colour: White

For dosage unit: weight: diameter: shape: logo/markings:


230mg 17.2mm x 6.3mm wide

2
Early-Warning System on New Psychoactive Substances Operating Guidelines
Annex III The EMCDDA-Europol Reporting Form

5. Circumstances: production trafficking distribution use

6. Price: retail (per dosage unit): wholesale:


€7 per capsule
7. Chemical precursors:
Not Known
8. Patterns of use:
Not Known
9. Other possible uses3:
Not Known
10. Effects in man
Not Known
Objectively observed:

Subjective (described by users):

11. Context of use


Not Known
User group(s):

Setting(s):

Availability at consumer level:


12. Indication on possible risks
Not Known
Health (individual):

Public health:

Social:
13. In case of production: large-scale small scale unknown

Has any form of organised crime been detected: yes no

14. In case of trafficking: large scale small scale unknown

national international

Has any form of organised crime been detected: yes no


15. In case of distribution: large-scale small scale unknown

Has any form of organised crime been detected: yes no

3
For example, for medical, industrial, ritual, cosmetic, etc., purposes

Вам также может понравиться